<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492112</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1705</org_study_id>
    <nct_id>NCT03492112</nct_id>
  </id_info>
  <brief_title>A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams</brief_title>
  <acronym>TEMPO</acronym>
  <official_title>A Non-randomized Trial to Evaluate a TEst and Treat Intervention Integrating Novel Point-of-care Hepatitis C RNA Testing, Linkage to Nursing Care, and Peer-supported Delivery of HCV Testing and Treatment aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TEMPO is an interventional cohort study recruiting injecting drug users attending needle and
      syringe programs (NSP) in Australia. Three hundred participants will be invited to on-site
      HCV testing with NSP integrated care for HCV treatment.

      Participants will be screened for HCV using point-of-care testing and HCV positive
      participants will be offered treatment with Sofosbuvir/Velpatasvir. Of those who initiate
      treatment, participants will receive weekly peer-based support on-treatment and return at End
      of Treatment (ETR) and 12 weeks following end of treatment (SVR12) for clinical follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uptake of HCV DAA therapy among current PWID</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Treatment uptake (i.e. proportion of participants initiating DAA therapy)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>People attending needle syringe programs in Australia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HCV RNA Point of Care</intervention_name>
    <description>Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.</description>
    <arm_group_label>People attending needle syringe programs in Australia</arm_group_label>
    <other_name>GeneXpert System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/velpatasvir</intervention_name>
    <description>Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.</description>
    <arm_group_label>People attending needle syringe programs in Australia</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/pibrentasvir</intervention_name>
    <description>Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.</description>
    <arm_group_label>People attending needle syringe programs in Australia</arm_group_label>
    <other_name>Maviret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Participants must meet all the following inclusion criteria to be eligible to participate
        in this study:

          1. Participants have voluntarily signed the informed consent form;

          2. 18 years of age or older;

          3. Current injecting drug use (previous month);

          4. HCV RNA positive participants commencing treatment must be eligible to initiate
             therapy with Sofosbuvir/Velpatasvir; and

          5. In the opinion of the Investigator, the participant is suitable for NSP-based HCV
             treatment delivery.

        Exclusion criteria

        1) For HCV RNA positive participants commencing treatment:

          1. Any clinically significant condition or history known to contraindicate the use of
             Sofosbuvir/Velpatasvir or would not be suitable for management within a NSP-based
             treatment setting;

          2. Any contraindicated medication in the Sofosbuvir/Velpatasvir product information;

          3. Has previous HCV DAA treatment experience

          4. Has a fibroscan score &gt; 12.5 Kpa

          5. HIV co-infection

          6. HBV co-infection

          7. Is female and is pregnant or breastfeeding

          8. Is unable or unwilling to provide informed consent or abide by the requirements of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Coordinator</last_name>
    <phone>+612 9385 0900</phone>
    <email>pmarks@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>NUAA NSP</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pip Marks</last_name>
      <email>pmarks@kirby.unsw.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

